A tier · strong
Genuine regulatory approvals and a very large clinical and post-market evidence base for dermal filling and ophthalmic surgery, held back from the top tier by contested efficacy in knee osteoarthritis where AAOS strongly recommends against routine use, and by a documented risk of vascular occlusion and blindness with facial injection.
hyaluronic acid (injectable)
Hyaluronic acid is not a peptide but an anionic, non-sulfated glycosaminoglycan polymer of repeating D-glucuronic acid and N-acetyl-D-glucosamine, used in FDA-regulated dermal fillers, intra-articular knee injections and ophthalmic viscoelastic devices. The dermal filler and ophthalmic uses rest on real approvals and large safety datasets, while intra-articular efficacy for knee osteoarthritis remains genuinely contested between major guideline bodies.
the explanation
Hyaluronic acid is a large sugar-based molecule that occurs naturally in skin, joints and eyes, and it is not a peptide at all. Injected versions are approved for smoothing facial wrinkles, cushioning arthritic knees and assisting eye surgery, but injecting it into the face can accidentally block a blood vessel and, rarely, cause permanent blindness.
regulatory status
FDA-regulated and approved/cleared for multiple injectable indications
Hyaluronic acid products are FDA-regulated for dermal filling of facial wrinkles and folds, for intra-articular injection in knee osteoarthritis, and as ophthalmic viscoelastic devices in cataract and corneal surgery. In 2018 the FDA published a Federal Register notice signalling intent to reconsider the appropriate classification of intra-articular hyaluronic acid products for knee osteoarthritis pain on the basis of scientific evidence, reflecting the unsettled efficacy picture in that indication.
how it works · proposed mechanism
Hyaluronic acid works primarily through physical and rheological properties rather than receptor pharmacology.
Volumetric space occupation
Crosslinked HA gels are highly hydrophilic and bind large volumes of water, providing physical volume and lift when placed in the dermis or subcutis. Filler duration of roughly 6 to 12 months reflects gradual enzymatic and mechanical degradation of the crosslinked network.
Viscoelastic joint lubrication
Native synovial HA of around 7 MDa contributes to boundary lubrication and shock absorption in the joint. Intra-articular injection aims to restore these rheological properties, though whether this translates into clinically meaningful pain relief is disputed.
Enzymatic reversibility
Because HA is a defined polysaccharide substrate, hyaluronidase can rapidly depolymerise injected material, and this is the established emergency intervention for filler-induced vascular occlusion. Reversibility is a substantive safety advantage over permanent fillers.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Hyaluronic acid is repeatedly listed alongside peptides in research-chemical catalogues, but it is a glycosaminoglycan polysaccharide with no amino acids and no peptide bonds, and its mechanism is physical rather than receptor-mediated. Its facial injection carries a small but real risk of arterial occlusion that can progress to tissue necrosis or permanent blindness within minutes, which is why the approved uses are procedural rather than self-administered.
key published findings
- Chemistry (structural): hyaluronic acid is an anionic, non-sulfated glycosaminoglycan of alternating D-glucuronic acid and N-acetyl-D-glucosamine linked by beta-(1 to 4) and beta-(1 to 3) bonds, CAS 9004-61-9; human synovial HA averages about 7 MDa or roughly 20,000 disaccharide monomers, so no single molar mass applies and it contains no peptide bonds.
- Human observational (Tamura et al., Annals of Plastic Surgery 2025, retrospective study of 290,307 HA injection sites in 209,083 patients): 10 vascular occlusions were identified, a rate of 0.0034 percent, including 8 forehead embolisations, plus 2 infections (0.0007 percent), for an overall severe complication rate of 0.0041 percent, with no blindness cases in this cohort.
- Human case-series evidence (Murray et al., Journal of Clinical and Aesthetic Dermatology 2021 guideline): cites a series of 28 severe hyaluronic acid embolism cases including 9 cases of blindness and 1 case of blindness with stroke, and notes that retinal damage can occur within 12 to 15 minutes of vascular occlusion; hyaluronidase is described as highly effective at dissolving crosslinked HA and preventing tissue necrosis.
- Human meta-analytic (Glinkowski & Tomaszewski, Journal of Clinical Medicine 2025, systematic umbrella review): intra-articular HA effect sizes for knee osteoarthritis ranged 0.30 to 0.40 versus placebo, below the typical minimal clinically important difference threshold of about 0.5 on WOMAC scales, with no compelling long-term superiority over alternatives.
- Guideline conflict (AAOS Clinical Practice Guideline Summary, JAAOS 2022, third edition): AAOS strongly recommends against intra-articular hyaluronic acid for knee osteoarthritis, whereas OARSI and ACR conditionally recommend it for patients unresponsive to other treatments, a direct disagreement driven by different thresholds for clinical significance.
limitations of the evidence
- Efficacy evidence is highly indication-dependent: strong for volumetric dermal filling and ophthalmic surgical use, contested for intra-articular knee osteoarthritis, and absent for systemic or cosmetic uses outside these approved contexts.
- The 290,307-site complication study is retrospective and single-source, so under-ascertainment of complications treated elsewhere cannot be excluded, and reported occlusion rates vary widely across the literature.
- HA products differ enormously in molecular weight, crosslinking chemistry and rheology, so safety and efficacy data from one product do not transfer reliably to another.
documented safety signals
- Intravascular injection during facial filling can cause arterial occlusion leading to skin necrosis and, rarely, permanent vision loss; a published case series documented 9 blindness cases and 1 blindness-with-stroke among 28 severe embolism cases.
- Retinal damage after ophthalmic artery occlusion is reported to occur within approximately 12 to 15 minutes, leaving a very narrow intervention window.
- A retrospective series of 290,307 injection sites reported a vascular occlusion rate of 0.0034 percent and an overall severe complication rate of 0.0041 percent, indicating these events are rare but not negligible at population scale.
- Infection at the injection site was documented at 0.0007 percent in the same series.
- Delayed inflammatory nodules, granuloma formation and filler migration are recognised late complications of dermal HA fillers.
- These risks are procedural and injector-dependent, which is why HA injection is regulated as a clinical procedure rather than a self-administered product.
identity
| full name | Hyaluronic acid / hyaluronan / sodium hyaluronate (injectable) |
| category | Cosmetic |
| modality | other |
| formula | (C14H21NO11)n repeating disaccharide unit; polydisperse polymer with no fixed formula |
| cas | 9004-61-9 |
laboratory handling
| storage | Commercial injectable HA is supplied in prefilled sterile syringes or vials, typically stored between 2 and 25 C per product labelling, protected from light and freezing. Product-handling information only. |
| solubility | Highly water-soluble and strongly hydrophilic; uncrosslinked HA dissolves in water to form viscous solutions, while crosslinked filler gels are hydrated networks rather than true solutions. |
| co-studied with | Not a peptide and not pharmacologically comparable to the other entries in this index; its inclusion in peptide catalogues is a categorisation error. Hyaluronidase is the established enzymatic countermeasure for injected HA and is documented in vascular occlusion management guidelines. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedAnnals of Plastic Surgery · 2025 · observational study
The Journal of Clinical and Aesthetic Dermatology · 2021 · clinical guideline
Journal of Clinical Medicine · 2025 · umbrella review
Journal of the American Academy of Orthopaedic Surgeons · 2022 · clinical guideline
US Federal Register (FDA) · 2018 · official document
Wikipedia · 2026 · reference
others in Cosmetic